Long-term outcomes of refractory Takayasu arteritis patients treated with biologics including ustekinumab
Biologics have been used to treat refractory Takayasu arteritis (TAK), but their efficacy and safety have not been sufficiently evaluated. We extracted clinical information from medical records for TAK patients who were treated with biologics including ustekinumab (UST) at Kyoto University Hospital....
Gespeichert in:
| Veröffentlicht in: | Modern rheumatology 2021-05, Vol.31 (3), p.678-683 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 683 |
|---|---|
| container_issue | 3 |
| container_start_page | 678 |
| container_title | Modern rheumatology |
| container_volume | 31 |
| creator | Gon, Yoshie Yoshifuji, Hajime Nakajima, Toshiki Murakami, Kosaku Nakashima, Ran Ohmura, Koichiro Mimori, Tsuneyo Terao, Chikashi |
| description | Biologics have been used to treat refractory Takayasu arteritis (TAK), but their efficacy and safety have not been sufficiently evaluated.
We extracted clinical information from medical records for TAK patients who were treated with biologics including ustekinumab (UST) at Kyoto University Hospital. We also analysed the patient's genetic backgrounds.
Of 163 cases, 12 (7.4%) were treated with infliximab, tocilizumab, or UST (n = 3). Erythrocyte sedimentation rate (ESR), C-reactive protein levels (CRP), and prednisolone (PSL) dose were significantly decreased 12 months after the initiation of biologics. When compared with the 15 patients who were only treated with immunosuppressants (IS group), the change in ESR from baseline was significantly lower in the biologics group than in the IS group (−2 mm/h, p = .005). The proportion of patients with HLA-B*52 and the risk-type alleles of the SNP were similar in both groups. Among the biologics, TCZ showed the highest continuation rate. UST exhibited marginal effects on reducing ESR, CRP levels, and PSL dose. No adverse events were observed in patients with UST for approximately 3 years.
Biological treatments resulted in a reduction in inflammatory markers and PSL dose in refractory TAK patients. |
| doi_str_mv | 10.1080/14397595.2020.1800560 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_32700985</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2426536061</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-1f42152aef14338369af480fc30cbc59d541ef5cacbcfd85113b2fa7fa95e86c3</originalsourceid><addsrcrecordid>eNp9kEtPxCAQgInR-P4JGo5eqkMp3XLTGF_JJl70TKYUVrQtK9CY_fey2V2PnuaRb2bgI-SCwTWDBm5YxeVMSHFdQplbDYCoYY8cr_vFrAa5v8szdEROYvwE4EI28pAc8XIGIBtxTNzcj4simTBQPyXtBxOptzQYG1AnH1b0Db9whXGiGDLmkot0icmZMUWagsFkOvrj0gdtne_9wulI3aj7qXPjgk4xmS83TgO2Z-TAYh_N-TaekvfHh7f752L--vRyfzcvNJeQCmarkokSjc2v5w2vJdqqAas56FYL2YmKGSs05sp2jWCMt6XFmUUpTFNrfkquNnuXwX9PJiY1uKhN3-No_BRVWZW14DXULKNig-rgY8x_VsvgBgwrxUCtLaudZbW2rLaW89zl9sTUDqb7m9ppzcDtBnCj9WHAHx_6TiVc9T5ksaN2UfH_b_wCUIKO4g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2426536061</pqid></control><display><type>article</type><title>Long-term outcomes of refractory Takayasu arteritis patients treated with biologics including ustekinumab</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><creator>Gon, Yoshie ; Yoshifuji, Hajime ; Nakajima, Toshiki ; Murakami, Kosaku ; Nakashima, Ran ; Ohmura, Koichiro ; Mimori, Tsuneyo ; Terao, Chikashi</creator><creatorcontrib>Gon, Yoshie ; Yoshifuji, Hajime ; Nakajima, Toshiki ; Murakami, Kosaku ; Nakashima, Ran ; Ohmura, Koichiro ; Mimori, Tsuneyo ; Terao, Chikashi</creatorcontrib><description>Biologics have been used to treat refractory Takayasu arteritis (TAK), but their efficacy and safety have not been sufficiently evaluated.
We extracted clinical information from medical records for TAK patients who were treated with biologics including ustekinumab (UST) at Kyoto University Hospital. We also analysed the patient's genetic backgrounds.
Of 163 cases, 12 (7.4%) were treated with infliximab, tocilizumab, or UST (n = 3). Erythrocyte sedimentation rate (ESR), C-reactive protein levels (CRP), and prednisolone (PSL) dose were significantly decreased 12 months after the initiation of biologics. When compared with the 15 patients who were only treated with immunosuppressants (IS group), the change in ESR from baseline was significantly lower in the biologics group than in the IS group (−2 mm/h, p = .005). The proportion of patients with HLA-B*52 and the risk-type alleles of the SNP were similar in both groups. Among the biologics, TCZ showed the highest continuation rate. UST exhibited marginal effects on reducing ESR, CRP levels, and PSL dose. No adverse events were observed in patients with UST for approximately 3 years.
Biological treatments resulted in a reduction in inflammatory markers and PSL dose in refractory TAK patients.</description><identifier>ISSN: 1439-7595</identifier><identifier>EISSN: 1439-7609</identifier><identifier>DOI: 10.1080/14397595.2020.1800560</identifier><identifier>PMID: 32700985</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>Adult ; Antibodies, Monoclonal, Humanized - therapeutic use ; Biological Products - therapeutic use ; Blood Sedimentation ; Female ; Humans ; IL-12 ; Immunosuppressive Agents - therapeutic use ; infliximab ; Infliximab - therapeutic use ; Male ; Middle Aged ; Takayasu arteritis ; Takayasu Arteritis - drug therapy ; tocilizumab ; Treatment Outcome ; ustekinumab ; Ustekinumab - therapeutic use</subject><ispartof>Modern rheumatology, 2021-05, Vol.31 (3), p.678-683</ispartof><rights>2020 Japan College of Rheumatology 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-1f42152aef14338369af480fc30cbc59d541ef5cacbcfd85113b2fa7fa95e86c3</citedby><cites>FETCH-LOGICAL-c390t-1f42152aef14338369af480fc30cbc59d541ef5cacbcfd85113b2fa7fa95e86c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32700985$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gon, Yoshie</creatorcontrib><creatorcontrib>Yoshifuji, Hajime</creatorcontrib><creatorcontrib>Nakajima, Toshiki</creatorcontrib><creatorcontrib>Murakami, Kosaku</creatorcontrib><creatorcontrib>Nakashima, Ran</creatorcontrib><creatorcontrib>Ohmura, Koichiro</creatorcontrib><creatorcontrib>Mimori, Tsuneyo</creatorcontrib><creatorcontrib>Terao, Chikashi</creatorcontrib><title>Long-term outcomes of refractory Takayasu arteritis patients treated with biologics including ustekinumab</title><title>Modern rheumatology</title><addtitle>Mod Rheumatol</addtitle><description>Biologics have been used to treat refractory Takayasu arteritis (TAK), but their efficacy and safety have not been sufficiently evaluated.
We extracted clinical information from medical records for TAK patients who were treated with biologics including ustekinumab (UST) at Kyoto University Hospital. We also analysed the patient's genetic backgrounds.
Of 163 cases, 12 (7.4%) were treated with infliximab, tocilizumab, or UST (n = 3). Erythrocyte sedimentation rate (ESR), C-reactive protein levels (CRP), and prednisolone (PSL) dose were significantly decreased 12 months after the initiation of biologics. When compared with the 15 patients who were only treated with immunosuppressants (IS group), the change in ESR from baseline was significantly lower in the biologics group than in the IS group (−2 mm/h, p = .005). The proportion of patients with HLA-B*52 and the risk-type alleles of the SNP were similar in both groups. Among the biologics, TCZ showed the highest continuation rate. UST exhibited marginal effects on reducing ESR, CRP levels, and PSL dose. No adverse events were observed in patients with UST for approximately 3 years.
Biological treatments resulted in a reduction in inflammatory markers and PSL dose in refractory TAK patients.</description><subject>Adult</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Biological Products - therapeutic use</subject><subject>Blood Sedimentation</subject><subject>Female</subject><subject>Humans</subject><subject>IL-12</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>infliximab</subject><subject>Infliximab - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Takayasu arteritis</subject><subject>Takayasu Arteritis - drug therapy</subject><subject>tocilizumab</subject><subject>Treatment Outcome</subject><subject>ustekinumab</subject><subject>Ustekinumab - therapeutic use</subject><issn>1439-7595</issn><issn>1439-7609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtPxCAQgInR-P4JGo5eqkMp3XLTGF_JJl70TKYUVrQtK9CY_fey2V2PnuaRb2bgI-SCwTWDBm5YxeVMSHFdQplbDYCoYY8cr_vFrAa5v8szdEROYvwE4EI28pAc8XIGIBtxTNzcj4simTBQPyXtBxOptzQYG1AnH1b0Db9whXGiGDLmkot0icmZMUWagsFkOvrj0gdtne_9wulI3aj7qXPjgk4xmS83TgO2Z-TAYh_N-TaekvfHh7f752L--vRyfzcvNJeQCmarkokSjc2v5w2vJdqqAas56FYL2YmKGSs05sp2jWCMt6XFmUUpTFNrfkquNnuXwX9PJiY1uKhN3-No_BRVWZW14DXULKNig-rgY8x_VsvgBgwrxUCtLaudZbW2rLaW89zl9sTUDqb7m9ppzcDtBnCj9WHAHx_6TiVc9T5ksaN2UfH_b_wCUIKO4g</recordid><startdate>20210504</startdate><enddate>20210504</enddate><creator>Gon, Yoshie</creator><creator>Yoshifuji, Hajime</creator><creator>Nakajima, Toshiki</creator><creator>Murakami, Kosaku</creator><creator>Nakashima, Ran</creator><creator>Ohmura, Koichiro</creator><creator>Mimori, Tsuneyo</creator><creator>Terao, Chikashi</creator><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20210504</creationdate><title>Long-term outcomes of refractory Takayasu arteritis patients treated with biologics including ustekinumab</title><author>Gon, Yoshie ; Yoshifuji, Hajime ; Nakajima, Toshiki ; Murakami, Kosaku ; Nakashima, Ran ; Ohmura, Koichiro ; Mimori, Tsuneyo ; Terao, Chikashi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-1f42152aef14338369af480fc30cbc59d541ef5cacbcfd85113b2fa7fa95e86c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Biological Products - therapeutic use</topic><topic>Blood Sedimentation</topic><topic>Female</topic><topic>Humans</topic><topic>IL-12</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>infliximab</topic><topic>Infliximab - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Takayasu arteritis</topic><topic>Takayasu Arteritis - drug therapy</topic><topic>tocilizumab</topic><topic>Treatment Outcome</topic><topic>ustekinumab</topic><topic>Ustekinumab - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gon, Yoshie</creatorcontrib><creatorcontrib>Yoshifuji, Hajime</creatorcontrib><creatorcontrib>Nakajima, Toshiki</creatorcontrib><creatorcontrib>Murakami, Kosaku</creatorcontrib><creatorcontrib>Nakashima, Ran</creatorcontrib><creatorcontrib>Ohmura, Koichiro</creatorcontrib><creatorcontrib>Mimori, Tsuneyo</creatorcontrib><creatorcontrib>Terao, Chikashi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Modern rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gon, Yoshie</au><au>Yoshifuji, Hajime</au><au>Nakajima, Toshiki</au><au>Murakami, Kosaku</au><au>Nakashima, Ran</au><au>Ohmura, Koichiro</au><au>Mimori, Tsuneyo</au><au>Terao, Chikashi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term outcomes of refractory Takayasu arteritis patients treated with biologics including ustekinumab</atitle><jtitle>Modern rheumatology</jtitle><addtitle>Mod Rheumatol</addtitle><date>2021-05-04</date><risdate>2021</risdate><volume>31</volume><issue>3</issue><spage>678</spage><epage>683</epage><pages>678-683</pages><issn>1439-7595</issn><eissn>1439-7609</eissn><abstract>Biologics have been used to treat refractory Takayasu arteritis (TAK), but their efficacy and safety have not been sufficiently evaluated.
We extracted clinical information from medical records for TAK patients who were treated with biologics including ustekinumab (UST) at Kyoto University Hospital. We also analysed the patient's genetic backgrounds.
Of 163 cases, 12 (7.4%) were treated with infliximab, tocilizumab, or UST (n = 3). Erythrocyte sedimentation rate (ESR), C-reactive protein levels (CRP), and prednisolone (PSL) dose were significantly decreased 12 months after the initiation of biologics. When compared with the 15 patients who were only treated with immunosuppressants (IS group), the change in ESR from baseline was significantly lower in the biologics group than in the IS group (−2 mm/h, p = .005). The proportion of patients with HLA-B*52 and the risk-type alleles of the SNP were similar in both groups. Among the biologics, TCZ showed the highest continuation rate. UST exhibited marginal effects on reducing ESR, CRP levels, and PSL dose. No adverse events were observed in patients with UST for approximately 3 years.
Biological treatments resulted in a reduction in inflammatory markers and PSL dose in refractory TAK patients.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>32700985</pmid><doi>10.1080/14397595.2020.1800560</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1439-7595 |
| ispartof | Modern rheumatology, 2021-05, Vol.31 (3), p.678-683 |
| issn | 1439-7595 1439-7609 |
| language | eng |
| recordid | cdi_pubmed_primary_32700985 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE |
| subjects | Adult Antibodies, Monoclonal, Humanized - therapeutic use Biological Products - therapeutic use Blood Sedimentation Female Humans IL-12 Immunosuppressive Agents - therapeutic use infliximab Infliximab - therapeutic use Male Middle Aged Takayasu arteritis Takayasu Arteritis - drug therapy tocilizumab Treatment Outcome ustekinumab Ustekinumab - therapeutic use |
| title | Long-term outcomes of refractory Takayasu arteritis patients treated with biologics including ustekinumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T18%3A15%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20outcomes%20of%20refractory%20Takayasu%20arteritis%20patients%20treated%20with%20biologics%20including%20ustekinumab&rft.jtitle=Modern%20rheumatology&rft.au=Gon,%20Yoshie&rft.date=2021-05-04&rft.volume=31&rft.issue=3&rft.spage=678&rft.epage=683&rft.pages=678-683&rft.issn=1439-7595&rft.eissn=1439-7609&rft_id=info:doi/10.1080/14397595.2020.1800560&rft_dat=%3Cproquest_pubme%3E2426536061%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2426536061&rft_id=info:pmid/32700985&rfr_iscdi=true |